JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.02B |
| 2 |
iShares US Treasury Bond ETF
GOVT
|
+$3.55B |
| 3 |
Eli Lilly
LLY
|
+$2.61B |
| 4 |
Amphenol
APH
|
+$2.33B |
| 5 |
TotalEnergies
TTE
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$9.67B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$7.48B |
| 3 |
Meta Platforms (Facebook)
META
|
+$7.25B |
| 4 |
NVIDIA
NVDA
|
+$6.05B |
| 5 |
Microsoft
MSFT
|
+$5.54B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.15% |
| 2 | Miscellaneous | 24.97% |
| 3 | Financials | 9.75% |
| 4 | Consumer Discretionary | 8.78% |
| 5 | Healthcare | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3901
PUT
New Fortress Energy
NFE
$37.5M
| $2.06M | ﹤0.01% |
36,154
+29,754
| +465% | +$2.19M |
2025 Q3
1 quarter
|
|
3902
Sabre
SABR
$795M
| $2.06M | ﹤0.01% |
1,513,637
+1,213,870
| +405% | +$2.09M |
2014 Q2
46 quarters
|
|
|
DFTX
3903
Definium Therapeutics
DFTX
$5.03B
| $2.06M | ﹤0.01% |
153,722
+110,540
| +256% | +$1.37M |
2021 Q2
18 quarters
|
|
3904
CALL
TripAdvisor
TRIP
$997M
| $2.05M | ﹤0.01% |
141,100
| – | – |
2025 Q3
1 quarter
|
|
3905
CALL
PTC Therapeutics
PTCT
$5.3B
| $2.05M | ﹤0.01% |
+27,000
| New | +$1.96M |
2025 Q4
0 quarters
|
|
|
3906
PUT
PTC Therapeutics
PTCT
$5.3B
| $2.05M | ﹤0.01% |
+27,000
| New | +$1.96M |
2025 Q4
0 quarters
|
|
3907
Invesco S&P International Developed Quality ETF
IDHQ
$1.05B
| $2.05M | ﹤0.01% |
58,266
-220
| -0.4% | -$7.61K |
2024 Q2
6 quarters
|
|
|
NXRT
3908
NexPoint Residential Trust
NXRT
$477M
| $2.05M | ﹤0.01% |
67,980
-22,577
| -25% | -$692K |
2015 Q4
40 quarters
|
|
3909
Lennar Class B
LEN.B
$19B
| $2.04M | ﹤0.01% |
21,473
-3,670
| -15% | -$416K |
2013 Q2
50 quarters
|
|
|
CNTA
3910
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.04M | ﹤0.01% |
81,486
-160,409
| -66% | -$4.06M |
2021 Q2
18 quarters
|
|
3911
iShares Residential and Multisector Real Estate ETF
REZ
$789M
| $2.03M | ﹤0.01% |
24,622
+7,912
| +47% | +$663K |
2016 Q1
39 quarters
|
|
|
HIVE
3912
HIVE Digital Technologies
HIVE
$817M
| $2.03M | ﹤0.01% |
787,261
+286,371
| +57% | +$1.21M |
2022 Q2
14 quarters
|
|
3913
Immunovant
IMVT
$6.94B
| $2.03M | ﹤0.01% |
79,866
+4,536
| +6% | +$101K |
2020 Q1
23 quarters
|
|
3914
Neuropace
NPCE
$436M
| $2.02M | ﹤0.01% |
130,926
+120,657
| +1,175% | +$1.61M |
2023 Q4
8 quarters
|
|
|
SBR
3915
Sabine Royalty Trust
SBR
$1.03B
| $2.02M | ﹤0.01% |
29,427
+14,065
| +92% | +$1.02M |
2023 Q3
9 quarters
|
|
|
CIM
3916
Chimera Investment
CIM
$775M
| $2.02M | ﹤0.01% |
162,296
-152,821
| -48% | -$1.94M |
2013 Q2
50 quarters
|
|
3917
State Street SPDR S&P 600 Small Cap Value ETF
SLYV
$4.79B
| $2.01M | ﹤0.01% |
22,138
+4,171
| +23% | +$375K |
2022 Q1
15 quarters
|
|
3918
Capital Group Core Balanced ETF
CGBL
$7.62B
| $2.01M | ﹤0.01% |
56,971
+33,965
| +148% | +$1.19M |
2025 Q2
2 quarters
|
|
3919
Organon & Co
OGN
$3.6B
| $2M | ﹤0.01% |
279,578
-40,769
| -13% | -$322K |
2021 Q2
18 quarters
|
|
|
NYAX
3920
Nayax
NYAX
$1.83B
| $2M | ﹤0.01% |
39,590
+15,863
| +67% | +$717K |
2024 Q4
4 quarters
|
|
|
ACRE
3921
Ares Commercial Real Estate
ACRE
$212M
| $2M | ﹤0.01% |
418,296
+41,481
| +11% | +$202K |
2015 Q3
41 quarters
|
|
3922
Kiniksa Pharmaceuticals
KNSA
$5.91B
| $2M | ﹤0.01% |
48,397
-144,059
| -75% | -$5.78M |
2024 Q3
5 quarters
|
|
3923
Grupo Aeroportuario Centro Norte
OMAB
$4.55B
| $1.99M | ﹤0.01% |
18,341
-3,632
| -17% | -$380K |
2016 Q3
37 quarters
|
|
3924
BOK Financial
BOKF
$7.8B
| $1.99M | ﹤0.01% |
16,833
-1,459
| -8% | -$164K |
2019 Q2
26 quarters
|
|
3925
Trump Media & Technology Group
DJT
$2.48B
| $1.99M | ﹤0.01% |
150,445
+83,821
| +126% | +$1.14M |
2021 Q4
16 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2025 Portfolio in Review
As of Q4 2025, JP Morgan Chase held 7,944 positions worth $1.59T, down 4.6% from $1.67T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
JP Morgan Chase withdrew a net $106B in Q4 2025, closing 563 positions and reducing 3,329 holdings. Its most notable exit was Interpublic Group of Companies, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, JP Morgan Chase opened a new position in Quadratic Interest Rate Volatility and Inflation Hedge ETF worth $99.9M.
- JP Morgan Chase's largest Q4 2025 buy was Quadratic Interest Rate Volatility and Inflation Hedge ETF: 5,216,227 shares worth $99.9M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q4 2025, an estimated $4.02B increase.
- JP Morgan Chase's biggest Q4 2025 reduction was Vanguard S&P 500 ETF, cutting an estimated $9.67B.
- JP Morgan Chase fully exited Interpublic Group of Companies in Q4 2025, selling an estimated $228M.
- JP Morgan Chase's ten largest holdings make up 26% of its $1.59T portfolio in Q4 2025.
- JP Morgan Chase opened 577 new positions and closed 563 in Q4 2025.
- JP Morgan Chase's portfolio value fell 4.6% quarter-over-quarter to $1.59T.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.